<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04607850</url>
  </required_header>
  <id_info>
    <org_study_id>HPV001</org_study_id>
    <nct_id>NCT04607850</nct_id>
  </id_info>
  <brief_title>Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions</brief_title>
  <official_title>A Phase 1b/2, Randomised, Placebo-controlled, Dose-ranging Study to Evaluate Safety, Tolerability and Immunogenicity of a Chimpanzee Adenovirus (ChAdOx1)-Vectored Multigenotype High Risk Human Papillomavirus (hrHPV) Vaccine and Modified Vaccinia Ankara (MVA)-Vectored Multigenotype hrHPV Vaccine in Women With Low-grade HPV-related Cervical Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaccitech (UK) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaccitech (UK) Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1b/2 multi-centre study evaluating the safety, efficacy and immunogenicity of&#xD;
      prime-boost vaccines ChAdOx1-HPV and MVA-HPV in women with HPV related low grade cervical&#xD;
      lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of an open label, non-randomised, dose escalation Lead in phase. 9&#xD;
      participants with high-risk HPV, in cohorts of 3 in 3 dose ascending groups, will be&#xD;
      vaccinated after SMC safety data reviews.&#xD;
&#xD;
      This is followed by a blinded, randomised Main phase with 96 participants with high-risk HPV,&#xD;
      in parallel running dose cohorts (three different doses of ChAdOx1-HPV plus two different&#xD;
      doses of MVA-HPV versus placebo plus placebo boost). At least 60 of these participants will&#xD;
      take part in the immunogenicity sub-study.&#xD;
&#xD;
      A blinded, randomised expansion phase investigating the effects of up to two different main&#xD;
      phase doses against placebo will be further defined prior to commencing this phase of the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Lead in phase will be open label. Main phase and expansion phase will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events to measure safety and reactogenicity</measure>
    <time_frame>3 months for the lead-in and 12 months for the main phase</time_frame>
    <description>Measure of adverse events, serious adverse events (SAEs), â‰¥Grade 3 study vaccine-related adverse events reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the dose of ChAdOx1-HPV plus MVA-HPV vaccines for further development</measure>
    <time_frame>3 months for lead in phase and 12 months for main phase</time_frame>
    <description>Measurement of the highest multi-parameter index made of CD4+ magnitude, CD4+ avidity and CD8+ magnitude at peak timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the effect of ChAdOx1-HPV plus MVA-HPV vaccines on the clearance of high risk HPV infection</measure>
    <time_frame>12 months for main phase only</time_frame>
    <description>The percentage of hrHPV infection clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the effect of ChAdOx1-HPV plus MVA-HPV vaccines on cervical intraepithelial neoplasia (CIN)</measure>
    <time_frame>12 months for main phase only</time_frame>
    <description>The percentage of cervical lesions cleared as determined by colposcopy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines</measure>
    <time_frame>3 months for lead in phase and 12 months for main phase</time_frame>
    <description>This will be assessed by measuring the individual phenotypic subsets of CD4+ and CD8+ T cells induced by vaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines</measure>
    <time_frame>3 months for lead in phase and 12 months for main phase</time_frame>
    <description>This will be assessed by measuring the innate immune response after vaccination compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines</measure>
    <time_frame>3 months for lead in phase and 12 months for main phase</time_frame>
    <description>This will be assessed by measuring the T cell breadth of response to the components of the ChAdOx1-HPV plus MVA-HPV vaccines</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines</measure>
    <time_frame>3 months for lead in phase and 12 months for main phase</time_frame>
    <description>Immune responses after prime and boost vaccinations in cytobrush samples compared to baseline</description>
  </other_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>HPV Infection</condition>
  <condition>CIN1</condition>
  <arm_group>
    <arm_group_label>Lead-in Group A ChAdOx1-HPV low dose and MVA-HPV low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^8 vp) and MVA-HPV (1 x 10^7 pfu)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lead-in Group B ChAdOx1-HPV mid dose and MVA-HPV low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^7 pfu)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lead-in Group C ChAdOx1-HPV high dose and MVA-HPV high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10) vp and MVA-HPV (1 x 10^8 pfu)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 ChAdOx1-HPV mid dose and MVA-HPV low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^7 pfu)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 ChAdOx1-HPV high dose and MVA-HPV low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10 vp) and MVA-HPV (1 x 10^7 pfu)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 ChAdOx1-HPV low dose and MVA-HPV high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^8 vp) and MVA-HPV (1 x 10^8 pfu)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 ChAdOx1-HPV mid dose and MVA-HPV high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^8 pfu)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 ChAdOx1-HPV high dose and MVA-HPV high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10 vp) and MVA-HPV (1 x 10^8 pfu)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6 Placebo Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride (0.9%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAdOx1-HPV</intervention_name>
    <description>Trial vaccine</description>
    <arm_group_label>Group 1 ChAdOx1-HPV mid dose and MVA-HPV low dose</arm_group_label>
    <arm_group_label>Group 2 ChAdOx1-HPV high dose and MVA-HPV low dose</arm_group_label>
    <arm_group_label>Group 3 ChAdOx1-HPV low dose and MVA-HPV high dose</arm_group_label>
    <arm_group_label>Group 4 ChAdOx1-HPV mid dose and MVA-HPV high dose</arm_group_label>
    <arm_group_label>Group 5 ChAdOx1-HPV high dose and MVA-HPV high dose</arm_group_label>
    <arm_group_label>Lead-in Group A ChAdOx1-HPV low dose and MVA-HPV low dose</arm_group_label>
    <arm_group_label>Lead-in Group B ChAdOx1-HPV mid dose and MVA-HPV low dose</arm_group_label>
    <arm_group_label>Lead-in Group C ChAdOx1-HPV high dose and MVA-HPV high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-HPV</intervention_name>
    <description>Trial vaccine</description>
    <arm_group_label>Group 1 ChAdOx1-HPV mid dose and MVA-HPV low dose</arm_group_label>
    <arm_group_label>Group 2 ChAdOx1-HPV high dose and MVA-HPV low dose</arm_group_label>
    <arm_group_label>Group 3 ChAdOx1-HPV low dose and MVA-HPV high dose</arm_group_label>
    <arm_group_label>Group 4 ChAdOx1-HPV mid dose and MVA-HPV high dose</arm_group_label>
    <arm_group_label>Group 5 ChAdOx1-HPV high dose and MVA-HPV high dose</arm_group_label>
    <arm_group_label>Lead-in Group A ChAdOx1-HPV low dose and MVA-HPV low dose</arm_group_label>
    <arm_group_label>Lead-in Group B ChAdOx1-HPV mid dose and MVA-HPV low dose</arm_group_label>
    <arm_group_label>Lead-in Group C ChAdOx1-HPV high dose and MVA-HPV high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline placebo vaccine</description>
    <arm_group_label>Group 6 Placebo Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females aged â‰¥25 and â‰¤55 years of age at screening.&#xD;
&#xD;
          2. Persistent hrHPV infection defined as a documented cervical infection with hrHPV&#xD;
             type(s) in the 6 to 18 months prior to screening and confirmed at screening&#xD;
             (participants in the main and expansion phases only). Participants in the lead-in&#xD;
             phase are only required to have the screening result.&#xD;
&#xD;
          3. Low- grade cervical lesion (CIN1 or HPV-related change only) confirmed by histology&#xD;
             and/or cytology report within the 1 year prior to screening.&#xD;
&#xD;
          4. Not pregnant or breast feeding and one of the following:&#xD;
&#xD;
               -  Of non-childbearing potential (i.e. women who have had a hysterectomy or tubal&#xD;
                  ligation or are postmenopausal, as defined by no menses for at least 12 months&#xD;
                  and without an alternative medical cause)&#xD;
&#xD;
               -  Of childbearing potential but agrees to practice highly effective contraception&#xD;
                  for 4 weeks prior to administration of the first dose of study vaccine and&#xD;
                  throughout the study until 8 weeks after administration of the second dose.&#xD;
                  Highly effective methods of contraception include one or more of the following:&#xD;
&#xD;
                    -  Male partner who is sterile (medically effective vasectomy) prior to the&#xD;
                       female participant's entry into the study and is the sole sexual partner for&#xD;
                       the female participant&#xD;
&#xD;
                    -  Hormonal (oral, intravaginal, transdermal, implantable or injectable).&#xD;
                       Progestogen-only hormonal contraceptives without inhibition of ovulation are&#xD;
                       not considered to be highly effective.&#xD;
&#xD;
                    -  An intrauterine hormone releasing system&#xD;
&#xD;
                    -  An intrauterine device&#xD;
&#xD;
                    -  Bilateral tubal occlusion&#xD;
&#xD;
                    -  Sexual abstinence, only if the participant refrains from heterosexual&#xD;
                       intercourse during the entire study period and it is the usual lifestyle of&#xD;
                       the participant&#xD;
&#xD;
          5. Willing to abstain from sexual activity for 48 hours prior to all swabbing procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of any significant acute or chronic, uncontrolled medical (or psychiatric)&#xD;
             illness, including blood dyscrasias.&#xD;
&#xD;
          2. Immunosuppression as a result of underlying illness or treatment including:&#xD;
&#xD;
               -  Use of high dose corticosteroids ( &gt;10 mg/day prednisone or equivalent) for â‰¥7&#xD;
                  days (inhaled, otic and ophthalmic corticosteroids are permitted)&#xD;
&#xD;
               -  Primary immune deficiency disease&#xD;
&#xD;
               -  Use of synthetic or biologic disease-modifying antirheumatic drugs&#xD;
&#xD;
               -  History of bone marrow or solid organ transplant&#xD;
&#xD;
               -  History of any other clinically significant autoimmune or immunosuppressive&#xD;
                  disease&#xD;
&#xD;
          3. Positive diagnostic tests (for human immunodeficiency virus, hepatitis B or hepatitis&#xD;
             C) indicating chronic infection.&#xD;
&#xD;
          4. Evidence of high grade cervical lesions by colposcopy or by Papanicolaou (Pap) smear&#xD;
             test in the 1 year prior to screening.&#xD;
&#xD;
          5. Any history of anaphylaxis in reaction to vaccination or history of allergic reactions&#xD;
             likely to be exacerbated by any component of the vaccine, e.g. severe allergy to eggs.&#xD;
&#xD;
          6. Receipt of any investigational drug or investigational vaccine within 3 months prior&#xD;
             to administration of ChAdOx1-HPV on Day 0, or prior participation in a clinical study&#xD;
             of any HPV vaccine.&#xD;
&#xD;
          7. Receipt of any adenoviral based vaccine within 3 months prior to administration of&#xD;
             ChAdOx1 HPV on Day 0, or plan to receive an adenoviral-based vaccine within 3 months&#xD;
             after Day 0.&#xD;
&#xD;
          8. Receipt of any live vaccines within the 30 days or inactivated vaccine within the 14&#xD;
             days prior to administration of ChAdOx1-HPV on Day 0 or planned to occur in the 2&#xD;
             months after the Day 0 vaccination.&#xD;
&#xD;
          9. Current or history of illicit drug use within the 6 months prior to screening.&#xD;
&#xD;
         10. Current or history of severe alcohol abuse within the 6 months prior to screening.&#xD;
&#xD;
         11. Any laboratory test which is abnormal and deemed by the Investigator to be clinically&#xD;
             significant which will potentially affect the participation in the study.&#xD;
&#xD;
         12. Current known infection with severe acute respiratory syndrome coronavirus 2 (SARS&#xD;
             CoV-2)&#xD;
&#xD;
         13. Any other finding that, in the opinion of the Investigator, deems the participant&#xD;
             unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participants must have a cervix in order to participate.</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>General Enquiries</last_name>
    <phone>(+44) 1865818808</phone>
    <email>enquiries@vaccitech.co.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wiebren Tjalma, MD</last_name>
      <email>Wiebren.Tjalma@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Francoise</last_name>
      <email>Francoise.Henry@erasme.ulb.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe DeSutter, MD</last_name>
      <email>Philippe.DeSutter@uzbrussel.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Leroux-Roels, MD</last_name>
      <email>cevac@uzgent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Willy Poppe, MD</last_name>
      <email>Willy.Poppe@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parnu Hospital Womens and Childrens Clinic</name>
      <address>
        <city>Parnu</city>
        <zip>80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kadri-Liina Vahula, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>East-Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10119</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inga Aavik, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Estonia Medical Centre Foundation Surgery Clinic</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kersti Kukk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital Womens Clinic</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Terje Raud, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Bristol NHS Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8EG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Newton, MD</last_name>
      <email>research_st.michaels@uhbristol.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Durham</name>
      <address>
        <city>Durham</city>
        <zip>DH1 5TW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Partha Sengupta, MD</last_name>
      <email>mwood8@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Women's NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L8 7SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paula Briggs, MD</last_name>
      <email>research@lwh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ursula Winters, MD</last_name>
      <email>Gynaecology.Research@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Russell, MD</last_name>
      <email>michelle.russell5@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospital NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ketankumar Gajjar</last_name>
      <email>ObsGynaeResearch@nuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Oxford, Nuffield Department of Women's &amp; Reproductive Health</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Hellner, MD</last_name>
      <email>hpv-study@wrh.ox.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Martin-Hirsch, MD</last_name>
      <email>Pierre.Martin-Hirsch@lthtr.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Estonia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

